Dawn Williams
Optometrist · Mc Lean, VANPI 1013200104
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,465 of the $7,565 with a category attached, or 85.5%. 26 manufacturers reported payments, led by AbbVie at 27.4% of the total. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Glaukos Corporation$728
- Sun Pharmaceutical Industries Inc.$629
- Visionary Optics LLC$600
- Tarsus Pharmaceuticals, Inc.$464
- Alcon$388
- plus $3K from 20 others
Across 7 payments — averaging $1363.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
What the payments were for
- Speaking & faculty fees$5007%
- Food & beverage$6,46585%
- Gifts$6008%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $2,075 |
| Glaukos Corporation | 10 | $728 |
| Sun Pharmaceutical Industries Inc. | 29 | $629 |
| Visionary Optics LLC | 1 | $600 |
| Tarsus Pharmaceuticals, Inc. | 19 | $464 |
| Alcon | 14 | $388 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $368 |
| Harrow Eye, LLC | 7 | $309 |
| Dompe US, Inc. | 10 | $304 |
| Bausch & Lomb Americas Inc. | 14 | $287 |
| Oyster Point Pharma, Inc. | 11 | $219 |
| Biotissue Holdings Inc. | 11 | $218 |
| Novartis | 10 | $214 |
| Kala Pharmaceuticals, Inc. | 9 | $180 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $117 |
| Astellas Pharma US Inc | 1 | $105 |
| Omeros Corporation | 6 | $96 |
| Rxsight Inc | 2 | $66 |
| Davol Inc. | 1 | $32 |
| Eyevance Pharmaceuticals LLC | 2 | $31 |
| Sanofi | 1 | $28 |
| Tearlab Corp | 1 | $24 |
| Eyepoint US, Inc. | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $21 |
| Sight Sciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent inject Trabecular Micro-Bypass Stent System$500
- Tecnis Simplicity$241
- VUITY$233
- LUMIGAN$125
- VEVYE$121
- DURYSTA$112
How this compares
$7,565 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 127 | $185,428 |
| XiidraLifitegrast | 44 | $72,036 |
| Cyclosporine | 46 | $27,745 |
| LumiganBimatoprost | 20 | $16,357 |
| VevyeCyclosporine | 13 | $9,846 |
| Loteprednol Etabonate | 20 | $2,393 |
| Latanoprost | 111 | $1,442 |
| Prednisolone Acetate | 57 | $1,362 |
| Doxycycline Monohydrate | 24 | $650 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 50 | $593 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $440 |
| Timolol Maleate | 25 | $377 |
| ErythromycinErythromycin Base | 14 | $169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,075 | $201,785147 claims |
| Bausch & Lomb Americas Inc.Xiidra | $287 | $72,03644 claims |
| Harrow Eye, LLCVevye | $309 | $9,84613 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $117 | $2,39320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.
Other optometrist in Mc Lean
- Walter WhitleyNorfolk$546K
- Jacqueline TheisRichmond$80K
- Joseph AllenRichmond$75K
- Keith SmithsonReston$74K
- Michael SwattsChesapeake$59K
- Kurt DevitoVirginia Beach$54K
- Walter SchlabachHarrisonburg$31K
- Mark AbrahamFalls Church$30K
- David TangVirginia Beach$29K
- Tiffany LioneAldie$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.